[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Early phase 1
- People taking part
- 2 people enrolled
- Started
- 31 Mar 2021
- Ended
- 30 Jul 2024
- Type of study
- Interventional
- Treatments tested
- [18F]Fluoroestradiol (FES) PET/CT
- Record updated
- 28 October 2024
- Why it stopped
- It was not feasible to perform FES PET/CT
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged 18 years or greater
- All patients or legal guardians are willing and able to sign written informed consent and HIPAA authorization in accordance with local and institutional guidelines
- Enrolled on the FORESEE trial
- Biopsy proven estrogen receptor positive breast cancer
- Patient deemed refractory to all combinations of hormonal therapies by FORESEE trial investigators
Who cannot take part
- Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion
- Patients who require monitored anesthesia for PET/CT scanning
- Patients who are too claustrophobic to undergo PET/CT scanning
- Patients who are pregnant or currently breast feeding
- Any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging
Where in United States
- Huntsman Cancer Institute at University of UtahSalt Lake City, United States
About the trial
What the trial wants to find out
This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.
The group in the trial
- Treatment: all patientsTreatment being tested
One session of \[18F\]FES PET/CT Imaging
Treatment: [18F]Fluoroestradiol (FES) PET/CT
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE: Functional Precision Oncology for Metastatic Breast Cancer Feasibility Trial
- Record updated
- 28 October 2024